FCGR3A and neoplasm: While engagement of CD16 has been one successful strategy of NKCE, other engagers have been designed to bridge the NKG2D activating receptor with tumor targets such as CS1 on multiple myeloma (MM) and HER2 on breast cancer cells (123, 124).